-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
- It is suitable for the treatment of unresectable or metastatic melanoma that has failed first-line treatment;
- Combined pemetrexed and platinum-based chemotherapy are suitable for the first-line treatment of metastatic non-squamous non-small cell lung cancer with negative epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) negative;
- Applicable to the first-line monotherapy of locally advanced or metastatic non-small cell lung cancer with EGFR gene mutation negative and ALK negative with PD-L1 tumor ratio score (TPS) ≥1% approved by the National Medical Products Administration;
- Combining carboplatin and paclitaxel is suitable for the first-line treatment of patients with metastatic squamous non-small cell lung cancer;
- A single agent is used to evaluate the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (comprehensive positive score (CPS) ≥ 10), have failed previous first-line systemic treatments, and have locally advanced or metastatic esophageal squamous cell carcinoma through fully validated tests
- The single agent is used to evaluate the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS≥20) through well-validated tests
